Robert Bermel, MD
Neurology · Cleveland, OHNPI 1932383932
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $216,132 of the $301,930 with a category attached, or 71.6%. It is spread thinly across 13 manufacturers, the largest accounting for just 23.6%. Reporting peaked in 2019 at $82,822 and has fallen 79.4% since, to $17,060 in 2025. Among neurology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $1312.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$71K
- Sanofi$58K
- Biogen$44K
- Genentech, Inc.$27K
- Novartis$26K
- TG Therapeutics, Inc.$23K
- plus $53K from 7 others
Across 155 payments — averaging $39,579 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$4.7M
- Genentech, Inc.$1.4M
- F. Hoffmann-la Roche AG$41K
- Novartis Pharma AG$4K
- Novartis$1K
What the payments were for
- Consulting fees$216,13272%
- Speaking & faculty fees$27,9939%
- Travel & lodging$51,11117%
- Food & beverage$5,8252%
- Education$8690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 43 | $71,256 |
| Sanofi | 33 | $57,633 |
| Biogen | 48 | $43,867 |
| Genentech, Inc. | 21 | $26,684 |
| Novartis | 21 | $25,877 |
| TG Therapeutics, Inc. | 13 | $23,421 |
| AstraZeneca(2 entities) | 4 | $22,850 |
| Genentech USA, Inc. | 22 | $13,963 |
| EMD Serono, Inc. | 17 | $11,360 |
| Merck Kgaa | 1 | $2,580 |
| Hoffmann-la Roche Limited | 3 | $1,823 |
| Penumbra, Inc. | 3 | $465 |
| Bristol Myers Squibb | 1 | $150 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$92,376
- BRIUMVI$12,900
- TYSABRI$12,637
- AUBAGIO$12,364
- TECFIDERA$8,867
- AVONEX$8,867
- PLEGRIDY$8,867
- Vumerity$8,867
- Mavenclad$6,876
- KESIMPTA$6,617
- Evobrutinib$3,870
- Enspryng$3,330
- DISEASE STATE$3,115
- GILENYA$1,276
- Real Immersive System$273
- MAYZENT$116
- Penumbra System$105
- ULTOMIRIS$100
How this compares
$301,930 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 11 | $90,641 |
Paid to pharmacies, not to this prescriber.
Other neurology in Cleveland
- Imad NajmCleveland$373K
- Hesham AbboudCleveland$363K
- Eric BaronCleveland$297K
- Robert FoxCleveland$296K
- Aarushi SunejaCleveland$269K
- Mary WillisCleveland$254K
- Benjamin WalterCleveland$210K
- Aasef ShaikhCleveland$186K
- Maryann MaysCleveland$173K
- Mary RenselCleveland$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.